SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Stopped The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.

Conditions

• Advanced Malignant Solid Neoplasm
• Metastatic Malignant Solid Neoplasm
• Unresectable Malignant Solid Neoplasm

Interventions

• BIOLOGICAL: Anti-TGF-beta Monoclonal Antibody SAR-439459
• BIOLOGICAL: Cemiplimab

Sponsor

M.D. Anderson Cancer Center